Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879075 | 1.00 | CCR1 (0.42) | CCR1KCNH2KMT2AMEN1LMNA | |
| SCHEMBL28438648 | 1.00 | CCR1 (0.42) | CCR1KCNH2KMT2AMEN1LMNA | |
| SCHEMBL29823495 | 0.87 | CCR3 (0.45) | KMT2AMEN1ALDH1A1CCR3 | |
| SCHEMBL1870607 | 0.87 | CCR3 (0.45) | KMT2AMEN1ALDH1A1CCR3 | |
| SCHEMBL5790256 | 0.80 | KMT2A (0.41) | KMT2AMEN1LMNAALDH1A1CCR3 | |
| SCHEMBL28433679 | 0.78 | PKM (0.45) | — | |
| SCHEMBL29823478 | 0.78 | PKM (0.45) | — | |
| SCHEMBL29823211 | 0.76 | KMT2A (0.50) | KMT2AMEN1ALDH1A1CCR3 | |
| SCHEMBL1873995 | 0.76 | KMT2A (0.50) | KMT2AMEN1ALDH1A1CCR3 | |
| SCHEMBL1872883 | 0.76 | MEN1 (0.41) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4143302-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCING HEMATOPOIETIC STEM AND PROGENITOR CELLS IN VIVO | Magenta Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022197776-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4051298-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |